ampreloxetine
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
4
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01458340)
Timeline
Indications
Mechanism of action
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Fc1cc(F)c(OCc2ccccc2C2CCNCC2)c(F)c1- Mol. weight
- 321.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297646 ↗
Also known as
- 4-(2-(2,4,6-trifluorophenoxymethyl)phenyl)piperidine
- td-9855
- td-9855
- td-9855
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05696717 | Phase 3 | Jun 27, 2023 | Theravance |
| NCT04688632 | Phase 1 | Jan 18, 2021 | Theravance |
| NCT04200573 | Phase 1 | Dec 17, 2019 | Theravance |
| NCT04095793 | Phase 3 | Sep 30, 2019 | Theravance |
| NCT03829657 | Phase 3 | Feb 22, 2019 | Theravance |
| NCT03750552 | Phase 3 | Jan 24, 2019 | Theravance |
| NCT03432793 | Phase 1 | Feb 28, 2018 | Theravance |
| NCT02705755 | Phase 2 | May 1, 2016 | Theravance |
| NCT01924143 | Phase 1 | Oct 1, 2013 | Theravance |
| NCT01693692 | Phase 2 | Nov 1, 2012 | Theravance |
| NCT01458340 | Phase 2 | Dec 1, 2011 | Theravance |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Theravance | For profit | 11 | 11 | 3 | 2011 |
1 organizations
Page 1 / 1